Thursday, March 16, 2017
Thursday, January 19, 2017
Stats of the year: 2016 By the Numbers
A review of the 2016 statistics from the multiple facets that make
up the healthcare arena includes:
- Television Commercials: A combined 1.3 million ads for prescription and over the counter drugs, raking in an estimated revenue of $4.6 million.
- Opioid Deaths: A nearly 20% increase in overdose deaths in Massachusetts attributed to the synthetic opioid, fentanyl.
- Expensive Drug Treatments: Only 3% of Kentucky Medicaid participants were able to receive hepatitis C treatments – a sign of the epidemic burdening the Medicaid system nationwide.
- Growth in Biotech: Private biotech companies received nearly $4 billion less in venture capital investment than in 2015.
Additional topics include
the gene editing technology, CRISPR; stem cell treatment facilities; the impact
of Zika on birth rates in Columbia; and hospice care utilization.
Read STAT News' article on it here.
Friday, December 30, 2016
Study: Patients Cared For by Female Doctors Fare Better Than Those Treated by Men
A new study, published in
Journal of the American Medical Association (JAMA) International, reports that
Medicare patients over the age of 80 were less likely to die or be readmitted
within 30 days if they were treated by a female doctor; estimates based on the
findings indicate that as many as 32,000 annual deaths may have been avoided if
the provider had been female. While the study does not draw conclusions
regarding why this is the case, anecdotally, experts hypothesize that females
are generally better communicators and have higher levels of emotional
intelligence. These skills play an important role in not only working with
patients, but also when working with the nurses who arrange discharge, social
work, home care, etc, and the family members who will play a large role in
treatment after discharge.
Listen to the NPR podcast on it here.
Listen to the NPR podcast on it here.
Monday, December 12, 2016
Chicago Will License Pharma Sales Reps to Fight Opioid Overprescribing
Chicago will enact a new
requirement that all pharmaceutical sales reps maintain a license based on
their training for ethics, marketing regulations and industry laws; at a cost
of $750, the reps will be responsible for applicable fees and annual renewals.
The new ordinance also requires paperwork to be filed with the city regarding
the reps’ activities and physician contact. The new regulations come after
Chicago filed lawsuits against multiple drug manufacturers and their role in
the current opioid epidemic. The fees are expected to exceed $1 million for the
city, which will then be used to support ongoing education efforts, regulatory
costs and expanding treatment availability for addicts. The pharmaceutical
industry argues that the new requirements do nothing to curb opioid abuse.
Read a Stat News article on it here.
Read a Stat News article on it here.
Tuesday, December 6, 2016
Should We Use Canada and The WHO's 'Essential Medicines' as Guides for US Drug Pricing?
Revamping
our Nation’s approach to drug pricing will be a daunting task and is one that
the public is expecting from our next president. Experts suggest a foundation
be built from two main sources:
- The World Health Organization’s (WHO) Essential Medicines list: Containing over 445 medicines deemed as essential in satisfying the priority health care needs of a population, the Essential Medicines list could serve as a model for the U.S. in identifying important drugs that should be protected from price surges and available to the entire population.
- The Canadian approach to drug pricing includes a review of efficacy, quality and safety; the proposed price by the manufacturer; prices of competing medications; and prices set in other countries. Negotiations for drug prices include the pan-Canadian Pharmaceutical Alliance and a price is determined for all provinces of the country.
Wednesday, November 23, 2016
[Podcast] A Powerful Duo Against HIV
Summary: Current treatment for HIV
is a lifelong regimen of antiretroviral drugs that place significant economic
and clinical stress on the patients being treated. Additionally, if individuals
stop taking these drugs, the virus quickly multiplies and rebounds to its
original levels. A major component in the weakening of the immune system by the
virus occurs through the destruction of immune cells in the gut. The virus
targets these cells, forcing the body to work continuously to repair the damage
and, subsequently, pulling needed resources from the rest of the immune system.
Researchers have developed a therapy to destroy the protein attached to the
cells that directs them to the gut and allows the body to mount a system-wide
immune response during infection. When used after a course of antiretrovirals,
monkeys receiving the new therapy have been able to control the infection
without additional treatments for two years. A safety study for use in humans
is currently underway.
You can hear the podcast here.
You can hear the podcast here.
Monday, October 31, 2016
A Cure for a Childhood Cancer - but Will It Last?
Article Summary: CAR-T, an experimental
treatment for cancer that supercharges the patient’s immune system by
genetically modifying immune cells, has had incredible results at high risks.
However, the risks of the treatment include death, though many of them are seen
as terminal without the treatment, and a new concern is that the cancer will
return. It is unknown if the results of the treatment are permanent or if the
cancer will return and, if it does, how quickly this will occur.
You can read MIT Technology Review's article on it here.
You can read MIT Technology Review's article on it here.
Subscribe to:
Posts (Atom)
